RI SB 2666
died on adjournmentAN ACT RELATING TO STATE AFFAIRS AND GOVERNMENT -- THE RHODE ISLAND MEDICAID REFORM ACT OF 2008
Rhode Island · 2026 Regular Session · upper
Quick answers
Did RI SB 2666 pass?
No. RI SB 2666 died when the 2026 Regular Session adjourned without final action on it. Bills that die this way are sometimes reintroduced in a later session. Latest recorded action (2026-02-27): 02/27/2026 Introduced, referred to Senate Finance
What is RI SB 2666 about?
Requires Medicaid to provide coverage for fertility medication, care, and services, for at least 3 cycles of fertility treatment, and intrauterine insemination.
Who sponsors RI SB 2666?
Valverde, Ujifusa, Lauria and 5 others are the primary sponsors of RI SB 2666.
Description
Requires Medicaid to provide coverage for fertility medication, care, and services, for at least 3 cycles of fertility treatment, and intrauterine insemination.
- Introduced
- 2026-02-27
- Latest action
- 2026-02-27 — 02/27/2026 Introduced, referred to Senate Finance
- Bill type
- bill
- Last updated
- —
Sponsors
- Valverdeprimary
- Ujifusaprimary
- Lauriaprimary
- Kallmanprimary
- Murrayprimary
- Guprimary
- DiMarioprimary
- Mackprimary
Committees
Not provided by source.
Action timeline
2026-02-27
02/27/2026 Introduced, referred to Senate Finance
introduction,referral-committee
Versions
- 2666Compare
Documents
Votes
Not provided by source.
Related bills
No related bills recorded for this bill.
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:31:46.990152Z
Inspect retained evidence for changes recorded after evidence tracking began:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=RI&identifier=SB 2666. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.